- Home
- ABEO vs LEGO Comparison
ABEO vs LEGO Comparison
Compare ABEO & LEGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$4.76
N/A
Current Price
$9.86
Company Overview
Basic Information| Metric | ABEO | LEGO |
|---|---|---|
| Founded | 1974 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.2M | 298.2M |
| IPO Year | 2005 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ABEO | LEGO |
|---|---|---|
| Price | $4.76 | $9.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 20.1K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $1,276.65 | N/A |
| Revenue Next Year | $112.53 | N/A |
| P/E Ratio | $4.77 | ★ N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $3.93 | $9.86 |
| 52 Week High | $7.54 | $9.91 |
Technical Indicators
Market Signals| Indicator | ABEO | LEGO |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 43.75 |
| Support Level | $4.53 | N/A |
| Resistance Level | $5.62 | N/A |
| Average True Range (ATR) | 0.20 | 0.02 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 71.53 | 0.00 |
Price Performance
Historical Comparison ABEO
LEGO
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.